Saleh A Alqahtani1, David E Kleiner2, Marwan Ghabril3, Jiezhun Gu4, Jay H Hoofnagle5, Don C Rockey6. 1. Division of Digestive and Liver Diseases, The University of Texas Southwestern, Dallas, Texas. 2. Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 3. Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana. 4. Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina. 5. Liver Disease Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland. 6. Division of Digestive and Liver Diseases, The University of Texas Southwestern, Dallas, Texas. Electronic address: rockey@musc.edu.
Abstract
BACKGROUND & AIMS: Cephalosporin antibiotics are popular because they have a broad spectrum of activity and are generally well tolerated; however, cephalosporin-induced liver injury is considered rare. We describe a new syndrome associated with a single intravenous dose of cefazolin and the clinical features of cephalosporin-induced liver injury. METHODS: The Drug-Induced Liver Injury (DILI) Network collected detailed clinical data on 1212 patients with DILI between 2004 and 2012. We analyzed data from 41 patients in whom cephalosporins were implicated as primary agents of liver disease; 33 formally were adjudicated as having cephalosporin-induced DILI. RESULTS: Nineteen patients developed clinically apparent DILI after a single intravenous dose of cefazolin. All patients developed self-limited liver injury 3 to 23 days after receiving cefazolin during surgery-often during a minor outpatient procedure. The latency period was 20 days. Clinical features included itching, jaundice, nausea, fever, and rash. Laboratory abnormalities included a mixed or cholestatic pattern of serum enzyme increases. We identified 14 more patients with DILI attributed to other cephalosporins (5 first-generation, 2 second-generation, 6 third-generation, and 1 fourth-generation agent). Although latency and injury patterns were similar for cefazolin and other cephalosporins, the other cephalosporins were associated with more severe courses of injury, including 2 deaths from liver failure. CONCLUSIONS: DILI can develop after a single dose of cefazolin. It is characterized by a latency period of 1 to 3 weeks after exposure, a cholestatic biochemical pattern, and a self-limited moderate to severe clinical course. Other cephalosporins can cause a similar but more severe injury.
BACKGROUND & AIMS:Cephalosporin antibiotics are popular because they have a broad spectrum of activity and are generally well tolerated; however, cephalosporin-induced liver injury is considered rare. We describe a new syndrome associated with a single intravenous dose of cefazolin and the clinical features of cephalosporin-induced liver injury. METHODS: The Drug-Induced Liver Injury (DILI) Network collected detailed clinical data on 1212 patients with DILI between 2004 and 2012. We analyzed data from 41 patients in whom cephalosporins were implicated as primary agents of liver disease; 33 formally were adjudicated as having cephalosporin-induced DILI. RESULTS: Nineteen patients developed clinically apparent DILI after a single intravenous dose of cefazolin. All patients developed self-limited liver injury 3 to 23 days after receiving cefazolin during surgery-often during a minor outpatient procedure. The latency period was 20 days. Clinical features included itching, jaundice, nausea, fever, and rash. Laboratory abnormalities included a mixed or cholestatic pattern of serum enzyme increases. We identified 14 more patients with DILI attributed to other cephalosporins (5 first-generation, 2 second-generation, 6 third-generation, and 1 fourth-generation agent). Although latency and injury patterns were similar for cefazolin and other cephalosporins, the other cephalosporins were associated with more severe courses of injury, including 2 deaths from liver failure. CONCLUSIONS: DILI can develop after a single dose of cefazolin. It is characterized by a latency period of 1 to 3 weeks after exposure, a cholestatic biochemical pattern, and a self-limited moderate to severe clinical course. Other cephalosporins can cause a similar but more severe injury.
Authors: U B Schaad; S Suter; A Gianella-Borradori; J Pfenninger; R Auckenthaler; O Bernath; J J Cheseaux; J Wedgwood Journal: N Engl J Med Date: 1990-01-18 Impact factor: 91.245
Authors: M Isabel Lucena; Raúl J Andrade; M Carmen Fernández; Ketevan Pachkoria; Gloria Pelaez; José A Durán; Macarena Villar; Luis Rodrigo; Manuel Romero-Gomez; Ramón Planas; Anabel Barriocanal; Joan Costa; Carlos Guarner; Sonia Blanco; José M Navarro; Fernando Pons; Agustin Castiella; Susana Avila Journal: Hepatology Date: 2006-10 Impact factor: 17.425
Authors: Don C Rockey; Leonard B Seeff; James Rochon; James Freston; Naga Chalasani; Maurizio Bonacini; Robert J Fontana; Paul H Hayashi Journal: Hepatology Date: 2010-06 Impact factor: 17.425
Authors: Hans L Tillmann; Ayako Suzuki; Huiman X Barnhart; Jose Serrano; Don C Rockey Journal: Curr Opin Gastroenterol Date: 2019-05 Impact factor: 3.287
Authors: Daniel J Selig; Geoffrey C Chin; Alexander G Bobrov; Jesse P DeLuca; Derese Getnet; Jeffrey R Livezey; Joseph B Long; Venkatasivasai S Sajja; Brett E Swierczewski; Stuart D Tyner; Vlado Antonic Journal: J Pharmacol Exp Ther Date: 2021-08-25 Impact factor: 4.030
Authors: Jawad Ahmad; Huiman X Barnhart; Maurizio Bonacini; Marwan Ghabril; Paul H Hayashi; Joseph A Odin; Don C Rockey; Simona Rossi; Jose Serrano; Hans L Tillmann; David E Kleiner Journal: J Hepatol Date: 2022-01-21 Impact factor: 25.083
Authors: Andrew S deLemos; Marwan Ghabril; Don C Rockey; Jiezhun Gu; Huiman X Barnhart; Robert J Fontana; David E Kleiner; Herbert L Bonkovsky Journal: Dig Dis Sci Date: 2016-03-22 Impact factor: 3.199